AN2 Therapeutics
ANTX
18 hedge funds and large institutions have $134M invested in AN2 Therapeutics in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
47.77% more ownership
Funds ownership: 0% → 47.77% (+48%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$55.6M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$24.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$21.5M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$10.4M |
| 5 |
DM
Deerfield Management
New York
|
+$8.86M |
Top Sellers
ANTX Hedge Fund Activity: Q1 2022 in Review
18 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q1 2022, worth a combined $134M.
Buyers outnumbered sellers: 18 funds opened new ANTX positions and 0 closed out — a net gain of 18 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $55.6M.
- 18 institutional investors held AN2 Therapeutics (ANTX) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $134M of AN2 Therapeutics stock for Q1 2022.
- 18 funds opened new AN2 Therapeutics positions in Q1 2022 and 0 closed out, a net change of +18 holders.
- The largest AN2 Therapeutics buyer in Q1 2022 was RA Capital Management, an estimated $55.6M added.
Based on aggregated 13F filings for Q1 2022.